Jan 20 (Reuters) - Isomorphic Labs, which uses

artificial intelligence for drug discovery, expects ‌to have its

first clinical ​trials by the end ‍of 2026, founder ⁠and ⁠CEO Demis

Hassabis said on ‌Tuesday.

The comments, ​made at an event at the ⁠World Economic ‍Forum

in ​Davos, Switzerland, signal a delay in the ‍Google-backed

startup's ambitions.

Hassabis had said last year the company would have

AI-designed drugs in ​clinical ‍trials by the end of 2025.

Isomorphic ​was founded in 2021 as a spin-off from Alphabet's

AI research subsidiary, Google DeepMind, which ​is headed by

Hassabis.